Juan Luis Chico García

Dr. Juan Luis Chico García

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2023 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
ÁBÁlvaro Beltrán-Corbellini
Álvaro Beltrán-Corbellini
MRMaría Romeral-Jiménez
María Romeral-Jiménez
PMPablo Mayo
Pablo Mayo
IRIrene Sánchez-Miranda Román
Irene Sánchez-Miranda Román
PIPablo Iruzubieta
Pablo Iruzubieta
AGAntonio Gil-Nagel
Antonio Gil-Nagel

22 November 2020 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PPPaloma Parra‐Díaz
Paloma Parra‐Díaz
JGJuan Luis Chico García
Juan Luis Chico García
ÁBÁlvaro Beltrán‐Corbellini
Álvaro Beltrán‐Corbellini
FJFernando Rodríguez Jorge
Fernando Rodríguez Jorge
CFClara Lastras Fernández‐Escandón
Clara Lastras Fernández‐Escandón
JMJuan Carlos Martinez-Castrillo
Juan Carlos Martinez-Castrillo
Background: Impulse control disorders (ICDs) have an increased frequency in patients with Parkinson's disease (PD), mainly because of treatment with dopamine agonists (DA). Factors related with the country of origin (culture, economy, healthcare politics) may impact phenomenology.Objectives: To explore phenomenology of ICDs depending on the country.Methods: A systematic review following PRISMA guidelines was performed using Pubmed database. Articles published up to 2018 in which the prevalence of ICDs was analyzed were selected.Results: Thirty‐two studies from 22 countries worldwide were included. The highest prevalence of ICDs in each continent was found in UK (59%), USA (39.1%) and India (31.6%). Frequency of ICDs was higher in those studies with lower mean age, higher proportion of males, whenever a screening instrument was used and whenever prescription of DAs was more common. Prevalence of ICDs was higher in Western countries compared to Asian countries (20.8% vs. 12.8%, P < 0.001) as it was the proportion of patients treated with DAs (66% vs. 48.2%, P < 0.001). Hypersexuality was the most common ICD overall (up to 23.8%). The highest frequencies of compulsive buying and eating were found in Western countries. Gambling was less commonly diagnosed, but prevalence was relevant Japan (14%).Conclusion: We observed a tendency towards a different ICD profile in different geographical areas, which may be attributable to socio‐economical, cultural or political influences in the phenomenology of these disorders. Acknowledging these differences could help their early detection, which is critical for prognosis.

13 February 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
EPEsteban Peña
Esteban Peña
CBCARMEN BORRUE
CARMEN BORRUE
MÁMarina Mata Álvarez-Santullano
Marina Mata Álvarez-Santullano
JMJuan Carlos Martinez-Castrillo
Juan Carlos Martinez-Castrillo
AAAraceli Alonso-Canovas
Araceli Alonso-Canovas
CRCristina Ruíz-Huete
Cristina Ruíz-Huete
Background: We aimed to assess the effects of safinamide on depression, motor symptoms, and the serotonin syndrome related to its co-administration with antidepressants in patients with Parkinson’s disease (PD). Methods: We retrospectively analyzed the data of patients at 1 and 3 months of follow-up compared to baseline. Results: n = 82 (safinamide 50 mg = 22, 100 mg = 60, with antidepressants = 44). First, we found improvement in depression (Hamilton Depression Rating Scale: −6 ± 5.10 at 1 month and −7.27 ± 5.10 at 3 months, p < 0.0001; Patient Global Impression of Improvement Scale: 60.3% and 69.5% of patients at 1 and 3 months reported some improvement). Second, safinamide improved the daily life activities and motor symptoms/motor complications (Unified Parkinson’s Disease Rating Scale (UPDRS-II): −2.51 ± 6.30 and −2.47 ± 6.11 at 1 and 3 months, p < 0.0001; III: −3.58 ± 8.68 and −4.03 ± 8.95 at 1 and 3 months, p < 0.0001; IV: −0.61 ± 2.61 and −0.8 ± 2.53 at 1 and 3 months, p < 0.0001). Third, 7.31% and 8.53% of patients developed non-severe adverse events related to safinamide at 1 and 3 months. Serotonin syndrome was not observed in the patients treated with antidepressants; some isolated serotonin syndrome symptoms were reported. Conclusions: Safinamide could be useful for treating depression in PD; it was effective for motor symptoms and motor complications and safe even when co-administered with antidepressants.

1 September 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ÁBÁlvaro Beltrán‐Corbellini
Álvaro Beltrán‐Corbellini
JGJuan Luis Chico García
Juan Luis Chico García
JMJavier Martínez‐Poles
Javier Martínez‐Poles
FRFernando Rodríguez‐Jorge
Fernando Rodríguez‐Jorge
AAAraceli Alonso‐Cánovas
Araceli Alonso‐Cánovas

Verified
Journal Article
Open access
PDF file
ARAlexander Rodero
Alexander Rodero
EMEnric Monreal
Enric Monreal
RSRaquel Sainz-Amo
Raquel Sainz-Amo
JDJose Manuel Garcia Dominguez
Jose Manuel Garcia Dominguez
NVNOELIA VILLARRUBIA
NOELIA VILLARRUBIA
LVLuisa Maria Villar
Luisa Maria Villar
Multiple studies have shown the importance of blood-based biomarkers indicating axonal damage (serum neurofilament light chains [sNfL]) or astroglia activation (serum glial fibrillary acidic protein [sGFAP]) for monitoring different neurological diseases. However, normal values of these variables remain to be clearly defined, partly due to the influence of different demographic factors. We investigated demographic differences in a cohort of healthy volunteers. A cross-sectional study was conducted including 116 healthy controls with ages between 18 and 69 years (67.5% females; n = 79). sNfL and sGFAP concentrations were measured using single-molecule arrays. Age and body mass index affected sNfL values, and age was found to be the most important factor. The normal values changed with age, and we established normal values for individuals younger than 45 years as <10 pg/mL and for controls older than 45 years as <15 pg/mL. We established normal values at <10 pg/mL for individuals younger than 45 years and <15 pg/mL for older individuals. Alternatively, a Z-score of 1.5 was relevant for all controls. sGFAP was only affected by age. Differences in normal values were evident by 55 years. The highest normality limit for sGFAP was 140 pg/mL for controls under 55 years and 280 for older controls. We defined normal levels for sNfL and sGFAP and their corresponding age-associated changes. These data may contribute to the application of such variables in clinical practice.

3 April 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
SMSusana Sainz de la Maza
Susana Sainz de la Maza
PWPaulette Esperanza Walo-Delgado
Paulette Esperanza Walo-Delgado
MRMario Rodriguez-Dominguez
Mario Rodriguez-Dominguez
EMEnric Monreal
Enric Monreal
ARAlexander Rodero
Alexander Rodero
LVLuisa Maria Villar
Luisa Maria Villar
Background: This study aimed to evaluate short- and long-term humoral and T-cell-specific immune responses to SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). Methods: Single-center observational longitudinal study including 102 patients with MS who consecutively received vaccination against SARS-CoV-2. Serum samples were collected at baseline and after receiving the second dose of the vaccine. Specific Th1 responses following in vitro stimulation with spike and nucleocapsid peptides were analyzed by quantifying levels of IFN-γ. Serum IgG-type antibodies against the spike region of SARS-CoV-2 were studied by chemiluminescent microparticle immunoassay. Results: Patients undergoing fingolimod and anti-CD20 therapies had a markedly lower humoral response than those treated with other DMTs and untreated patients. Robust antigen-specific T-cell responses were detected in all patients except those treated with fingolimod, who had lower IFN-γ levels than those treated with other DMTs (25.8 pg/mL vs. 868.7 pg/mL, p = 0.011). At mid-term follow-up, a decrease in vaccine-induced anti-SARS-CoV-2 IgG antibodies was observed in all subgroups of patients receiving DMTs, although most patients receiving induction DMTs or natalizumab and non-treated patients remained protected. Cellular immunity was maintained above protective levels in all DMT subgroups except the fingolimod subgroup. Conclusions: SARS-CoV-2 vaccines induce robust and long-lasting humoral and cell-mediated specific immune responses in most patients with MS.